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Status epileptics (SE) and cluster seizures (CS) are serious neurological emergencies
associated with poor outcome in epileptic patients. Data on risk factors associated with
outcome in epileptic patients affected by CS and SE have not been studied extensively
to date. In the present retrospective study potential risk factors predictive of negative
outcome in a population of dogs affected by CS and SEwere analyzed. Ninety-three dogs
were included in the study: 21/93 patients (23%) presented with SE and 72/93 (77%) with
CS. Based on multivariate statistical analysis, factors statistically associated with a poor
outcome were the occurrence of the first epileptic seizure outside the defined idiopathic
interval (6 months−6 years), a condition of hyperthermia at presentation and the absence
of previous antiepileptic drugs (AEDs) in case of previous history of seizures. The results of
the present study implement data on risk factors associated with poor outcome in dogs
affected by CS or SE and can aid in the creation of an ad hoc scoring system, similar
to systems currently applied in human medicine upon hospital admission to benchmark
performances and establish protocols for triage and therapeutic management.
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INTRODUCTION
Status epilepticus (SE) and cluster seizures (CS) are serious neurological emergencies that require
rapid diagnosis and treatment. They are major risk factors for euthanasia and spontaneous
death and associated with poor outcome in epileptic patients (1–5). Risk factors associated with
outcome in canine patients affected by SE and CS have not been studied extensively and data
are limited (2–7). With this study we wanted to investigate and evaluate risk factors predictive of
negative outcome in a population of dogs affected by CS or SE, directly assessable upon admission
of patients.
MATERIALS AND METHODS
Study Population and Data Collection
For this study we manually reviewed the medical records of dogs admitted to the Veterinary
Teaching Hospital, Department of Veterinary Sciences, University of Turin, between July 2015,
Cagnotti et al. Risk Factors CS and SE
and February 2019 for CS or SE. The inclusion criterion was
SE or CS confirmed by historical description of owners or
visual inspection at admission and/or during the hospitalization.
All patients underwent at least one neurological examination
performed by a board-certified neurologist (ADA) or a
neurologist in training (GC) under the supervision of the
board-certified neurologist. In cases of multiple hospital stays
because of SE or CS during the study period, only the first
stay was used for analysis. Data extracted from the charts
included: sex, neutering status, breed, size, brachycephalic
morphology, age at hospitalization, age at first seizure, seizure
type (focal vs. generalized), seizure presentation (CS or SE),
emergency treatment protocol, history of previous seizures,
previous antiepileptic drug (AED) therapy in epileptic patients,
seizure etiology, comorbidity, in-hospital complications, lactate
and glucose blood concentration at admission, rectal temperature
at admission, heart rate and respiratory rate and pattern at
admission, and outcome. Outcome was defined as death in
hospital or hospital discharge. Missing medical chart data was a
reason for exclusion from the study.
Definitions
Signalment and Age at Hospitalization
Signalment information was collected from the patient’s medical
records. The patients were classified by sex and reproductive
status: intact males, neutered males, intact females, and
neutered females. Breed and brachycephalic morphology were
defined according to American Kennel Club (https://www.akc.
org/) and UK Kennel Club (https://www.thekennelclub.org.uk/)
definitions. To determine whether brachycephalic morphology
was present in cross breeds, we called the owners and asked
whether the dog’s muzzle was comparable to that of a typical
brachycephalic breed (e.g., pug). Age at hospitalization was
expressed in months.
Comorbidity
Comorbidity was defined as the presence of disease(s) other
than the index disease in an individual (8). Medical conditions
observed were classified into cardiac, respiratory, urinary,
infectious and parasitic, gastro-enteric, respiratory, gastro-
enteric, endocrine, neoplastic, ophthalmologic, neurologic, and
locomotor disorders.
Comorbidities were also classified by their impact on the
patient’s health status: those likely to be incidental and those
possibly affecting current health status and/or seizure control.
Clinical chart review and classification of diseases was performed
by two of the authors (GC and ADA) blinded to patient outcome.
Presentation
SE and CS were defined according to the International Veterinary
Epilepsy Task Force consensus report. SE was defined as a
seizure activity lasting more than 5min or as the occurrence
of two or more epileptic seizures without complete recovery
Abbreviations: SE, Status Epilepticus; CS, Cluster Seizures; AED, Antiepileptic
Drug; IQR, Interquartile Range; SD, Standard Deviation; PB, phenobarbital; CI,
Confidence Interval; OR, Odd Ratio.
of consciousness in between. CS were clinically defined as the
occurrence of two or more epileptic seizures within 24 h (9).
Type of Seizure Activity
Seizure type was categorized as focal or generalized. Criteria
for categorization as focal seizure included clinical signs (motor,
autonomic or behavioral signs, alone or combined) in relation to
the function of the area affected by abnormal electrical neuronal
activity within one hemisphere. Generalized epileptic seizure was
defined as seizure activity affecting both sides of the body and
resulting from bilateral involvement of the cerebral hemisphere
(9). Only convulsive epileptic seizures (tonic-clonic, tonic,
clonic, and myoclonic) were evaluated for this study because
electroencephalographic confirmation of non-convulsive seizure
activity was unavailable.
Complications
In-hospital complications were defined as secondary
complications that developed during hospital stay (10).
Age at First Seizure, Idiopathic Interval and History of
Previous Seizures
History of prior seizures and age at first seizure (expressed in
months) were recorded. As seizure onset between age 6 months
and 6 years is commonly assumed to be more probably associated
with a diagnosis of idiopathic epilepsy (11), this time period was
defined as the idiopathic interval.
Previous AED Therapy
Information on previous antiepileptic treatment was collected
from the medical records of patients with a history of seizures.
Seizure Etiology
Data regarding seizure etiology were collected from
medical records.
Seizure etiology included: reactive seizures, idiopathic
epilepsy (Tier I and Tier II) and structural epilepsy (suspected
or confirmed). Reactive seizures were suspected based on a
history of possible exposure to toxic agents or based on the
results of hematological laboratory tests (9). A diagnosis of
idiopathic epilepsy was made according to the International
Veterinary Epilepsy Task Force consensus report (Tier I and Tier
II confidence level) (11). Structural epilepsy was diagnosed when
reactive causes of seizures were excluded, along with signalment,
history, an abnormal interictal neurological examination
(suspected structural epilepsy) and magnetic resonance imaging
and cerebrospinal fluid analysis results (confirmed structural
epilepsy) (11).
However, considering the aim of the present study this
variable was not taken into consideration for statistical analysis,
since seizure etiology is not always available upon admission
for all epileptic patients before diagnostic investigations
are performed.
Lactate and Glucose Concentration
A venous blood sample was taken upon admission during
systemic stabilization of patients and analyzed by means
of a blood gas analyzer (ABL825 Flex Blood Gas Analyzer,
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Radiometer Medical ApS, Denmark). Lactate blood
concentration reference values were between 2.7 and 22.5
mg/dL (0.3–2.5 mmol/L) (12). Hyperlactemia between 23.4
and 54 mg/dL (2.6 and 6 mmol/L) was defined as mild to
moderate; lactate blood concentrations > 54 mg/dL (6 mmol/L)
were defined as severe hyperlactemia (12, 13). Glucose blood
concentration reference values were between 60 and 130 mg/dL
(14). Blood levels below the lower limit indicated hypoglycemia
and levels above the upper threshold indicated hyperglycemia.
Rectal Temperature, Heart Rate and Respiratory Rate
and Pattern
Variables were measured upon admission, during systemic
stabilization of patients and classified according to reference
values based on size: dogs weighing 4–10 kg were classified
as small; the normal range for temperature was 38.5–39.2◦C,
the heart rate was 80–180 beats per minute (bpm), and the
respiratory rate was 24–36 breaths per minute. Dogs weighing
11–25 kg were categorized as medium; the normal range for
temperature was 38–39◦C, the heart rate was 80–160 bpm,
and the respiratory rate was 20–32 breaths per minute. Dogs
weighing > 25kg were classified as large; the normal range
for temperature was 37.5–38.5◦C, the heart rate was 60–80
bpm, and the respiratory rate was 16–25 breaths per minute.
In puppies (dogs up to age 9 months), the normal range for
temperature was 38.5◦C for the first month and then according
to size as described for adults, the heart rate up to 220 bpm,
and the respiratory rate from 20 to 40 breaths per minute
(15). Furthermore, signs of dyspnea were also recorded. Size
classification was based on body weight and standard size for
breed; reference values were taken from the Royal Canine
guidelines (https://www.royalcanin.com/us).
Outcome
Poor outcome was defined as death in hospital by euthanasia or
spontaneous death. Survivors were discharged after 24 h of being
seizure-free or after at least 24 h after discontinuation of drug-
induced coma in the absence of seizure activity and according
to self-sufficiency.
Statistical Analysis
Data were analyzed using commercially available software
programs [Excel [Microsoft] version 16.27 [19071500]; R
commander graphical interface R version 3.3.2 [2016-10-31]].
Standard descriptive statistics are reported as median and
interquartile range (IQR) or mean and standard deviation
(± SD) for continuous variables and percentage and frequency
for categorical variables. Continuous variables were tested for
normality distribution using the Shapiro-Wilk test and revealed
a non-normal distribution. Numerical data were tested using
the Wilcoxon ranked-sum test, while categorical variables were
compared using the Chi-square or Fisher’s two-tailed exact
tests when appropriate. Categorical variables were: sex and
neutering status, breed, size, brachycephalic morphology, seizure
presentation, comorbidity, complications, idiopathic interval,
history of previous seizures, previous AED therapy, seizure type,
and respiratory rate and pattern; continuous variables were
age at first seizure, age at hospitalization, rectal temperature,
heart rate, glucose and lactate blood concentrations. Rectal
temperature, heart rate, glycemic level, and blood lactate level
were categorized for statistical purposes, as previously reported.
Statistical significance was set at P < 0.05. A P-value between
0.05 and 0.10 was defined as a trend. Variables were also assessed
individually with univariate logistic models. Following these
analyses, variables with a P < 0.10 were entered in multivariate
analysis models to identify the most explicative model. Models
were compared by analyzing the level of fitness of the model
with McFadden’s pseudo R squared. Factors were considered
significant when the P < 0.05.
RESULTS
A total of 134 dogs were presented for CS or SE during the
period of study. Ninety-three patients met the inclusion criteria.
Thirty-six (39%) of the final population of 93 dogs were female
(19 intact, 17 neutered) and 57 (61%) were male (51 intact, six
neutered). The most common breeds were cross breed (32/93),
German Shepherd (8/93), and French Bulldog (7/93), followed
by three dogs of the breed: American Staffordshire Terrier,
Boxer, Chihuahua, Corso dog, two dogs of the breed: Yorkshire,
Border Collie, Cocker Spaniel, English Bulldog, Poodle, and
Pekinese, and one dog of the breed: Australian Shepherd, Beagle,
Bernese Mountain dog, Epagneul Breton, Cavalier King Charles
Spaniel, CzechoslovakianWolf, Dachshund, Dogue de Bordeaux,
Pinscher, Giant Schnauzer, Golden Retriever, Labrador Retriever,
Maltese, Miniature Schnauzer, Pitbull Terrier, Pomeranian Spitz,
Pug, Shih tzu, Siberian Husky, St. Bernard, and Weimaraner.
The sample included 27/93 (29%) brachycephalic dogs and was
categorized by size in: 34/93 (36%) large, 23/93 (25%) medium,
and 36/93 (39%) small breed dogs.
The median age at hospitalization was 88 months (IQR
48–134); the median age at first seizure was 72 months (IQR
24–120). The age at first seizure was within the idiopathic interval
in 46/93 dogs (50%). The first seizure occurred before 6 months
of age in 4/93 (4%) and after age 6 years in 43/93 (46%). History
of previous seizures was recorded in 52/93 dogs (56%), 25 of
which were on previous AED treatment for seizure control. In
detail, 19 were receiving 1 medication: 14 with phenobarbital
(PB), four with imepitoin, and one with gabapentin; four dogs
were receiving 2 AEDs: two with PB and levetiracetam, one
with PB and carbamazepine, and one with PB and potassium
bromide; two were receiving three AEDs: one with PB, imepitoin,
and diazepam, and one with PB, potassium bromide, and
levetiracetam. In all but one of these 25 cases, the minimal
duration of AED therapy before hospitalization was at least 1
month. The duration of previous AED therapy was unknown in
1 patient. The median time between age at first seizure and age
at hospitalization was 12 months (IQR 7–22) in the patients on
antiepileptic treatment and 9 months (IQR 1–34) in those not
receiving an AED.
Forty-five of 93 patients were diagnosed with structural
epilepsy (20/45 confirmed and 25/45 suspected), 27/93 with
idiopathic epilepsy (8/27 Tier II confidence level and 19/27 Tier
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I confidence level), and 14/93 with epilepsy of unknown origin.
Seven out of 93 patients were diagnosed with reactive seizures
(1/7 metaldehyde intoxication, 6/7 hypoglycemia).
A total of 21/93 patients (23%) presented with SE and 72/93
(77%) with CS. Generalized and focal seizures occurred in 87/93
(94%) and 6/93 (6%) dogs, respectively.
The emergency treatment protocol was the same for all
patients included in the study: rectal/intravenous diazepam (1–2
mg/kg if the patient was seizuring at presentation) followed by
intravenous phenobarbital (4–5 mg/kg q8 h).
Comorbidities were present in 27/93 (29%) dogs; in-hospital
complications developed in 6/93 (6%). Complications included:
infection (3/6), acute lung injury (1/6), acute kidney insufficiency
(1/6), atrial fibrillation and cardiac arrest (1/6).
The median blood glucose level was 109 mg/dL (IQR
96–127); hyperglycemia (median 142.5 mg/dL; IQR 135–162)
was recorded in 20/93 (21%) dogs and hypoglycemia (median 49
mg/ dL; IQR 35–53) in 9/93 (10%). Themedian lactate blood level
was 20.7 mg/dL (IQR 12.6–35.1); mild hyperlactatemia (median
35.1 mg/dL; IQR 27.9–41.4) was recorded in 33/93 (35%) dogs,
and severe hyperlactatemia (median 94.6 mg/dL; IQR 72–133.3)
in 9/93 (10%).
The median temperature was 38.6◦C (IQR 38.2–39.2◦C).
Hyperthermia (median 39.6◦C; IQR 39.1–40◦C) was recorded
in 34/93 (37%−18/34 large size, 10/34 medium size, and 6/34
small size) and hypothermia (median 38◦C; IQ: 37.8–38.2◦C)
in 17/93 (18%−1/17 medium size, 16/17 small size dogs). The
median heart frequency was 120 bpm (IQR 100–140); tachycardia
(median 120 bpm; IQR 100–140) was recorded in 33/93 dogs
(36%−30/33 large size, 3/33 medium size), and bradycardia
(median 71 bpm; IQR 67.5–72.5) in 4/93 (4%−3/4 large size and
1/4 medium size). Tachypnea was recorded in 71/93 (76%−30/71
large size, 18/71 medium size, 23/71 small size) and bradypnea
in 6/93 (7%−1/6 medium size, 5/6 small size); a dyspneic
respiratory pattern was present in 1 dog (1%).
Seventy-two (77%) patients were discharged alive from the
hospital, while 21/93 (23%) died during hospital stay: 5 of
spontaneous death (cardiorespiratory arrest), accounting for 5%
of the study population, and 16 (17%) by euthanasia. None
were euthanized for economic reasons but rather because of the
persistence of uncontrolled seizure activity despite treatment or
severe worsening of the neurological condition. Only one dog
that recovered from the seizure activity was euthanized by the
owner’s request because diagnosed with metastatic lung disease
prior to admission.
Statistical analysis revealed a trend for the difference in age
at first seizure between survivors (median 61 months, IQR
24–100) and non-survivors (median 120 months, IQR 43–156)
(P = 0.05). Furthermore, comparison of the outcome in patients
with an age at first seizure inside or outside the idiopathic
interval showed a mild association: death was more frequent
among patients experiencing the first epileptic seizure outside
the defined idiopathic interval [P = 0.09; odds ratio [OR]
2.34; confidence interval [CI] 0.77–7.72]. Hospital deaths were
recorded for 2 of the 4 (50%) that had experienced their first
episode before age 6 months, 13 of the 43 (30%) that had
experienced their first seizure after 6 years of age, and for 6 of
the 46 (13%) for which the age at first seizure was within the
idiopathic interval.
The in-hospital complications rate was higher among patients
with poor outcome (P = 0.02; OR 7.9; CI 1.05–95.15).
Comorbidity stratification revealed an association with
outcome: fatal outcome was almost 17 times higher in
patients with comorbidity affecting current health status or
control of seizure activity than in those with incidental
comorbidities (P = 0.02).
The median rectal temperature was 38.5◦C (IQR 38.2–39◦C)
and 38.9◦C (IQR 38.5–40◦C) in survivors and non-survivors,
respectively; this difference was statistically significant (P= 0.02).
When we stratified temperature in low, normal, and high
by body size, the risk of death was higher in patients with
hyperthermia (P = 0.08).
In patients with a history of seizures, those not receiving
previous AED therapy were more likely to experience a poor
outcome (P = 0.01; OR 11.5, CI 1.38–545.73). No other
associations were found (Supplementary Table 1).
In order to build a predictive model with the most informative
variables, univariate logistic analyses confirmed the associations
highlighted by statistical analysis: age at first seizure (P = 0.03,
OR 1.01, CI 1.00–1.02), previous AED treatment (P = 0.02,
OR 12.00, CI 1.99–232.56), rectal temperature (P = 0.04, OR
3.27, CI 1.11–10.64), presence of comorbidities (P = 0.02, OR
16.7, CI 2.02–416.67), and complications (P = 0.02, OR 8.23,
CI 1.48–63.06) were statistically associated with outcome. A
trend was found for age at first seizure inside or outside the
idiopathic interval (P = 0.09, OR 2.38, CI 0.88–6.90). Based
on statistical criteria these variables underwent further analysis.
Table 1 presents the associations and their statistical values.
The most explicative and clinically most significant
multivariate model was selected as the final one. Rectal
temperature, idiopathic interval, and previous AED treatment
were the only variables that retained significance: hyperthermia
(P = 0.005, OR 6.67, CI 1.84–27.67), first seizure outside the
idiopathic interval (P = 0.04, OR 3.57, CI 1.11–13.33), and
absence of previous AED therapy in dogs with a history of
seizures (P = 0.01, OR 16.67, CI 2.90–436.61) were associated
with death (Table 2). Further analyses to evaluate specific
associations between variables and clinical presentation revealed
a statistically significant association between hypoglycemia and
SE presentation (P= 0.03, OR: 5.82; CI: 1.07–34.54) and between
hyperthermia and SE presentation (P = 0.03, OR: 6.48; CI:
1.64–30.66) (Supplementary Table 2).
DISCUSSION
The early assessable parameters associated with a negative
outcome in dogs with CS or SE were absence of a previous
AED therapy in dogs with a history of seizures, age at first
seizure outside the defined idiopathic interval, and elevated
rectal temperature at presentation. To our best knowledge, the
literature on risk factors for spontaneous death or euthanasia
in epileptic dogs is scant, and information on dogs affected by
CS or SE is even more limited (2–7). With the present study
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TABLE 1 | Univariate analysis.
Univariate analysis Estimate OR P-value 95% CI (2.5–97.5%)
Previous AED in epileptic patients (no vs. yes) 2.48 1.25 0.02 1.99–232.56
Age at first seizure (months) 0.10 1.01 0.03 1.001–1.02
Complication (yes vs. no) 2.10 8.23 0.02 1.48–63.06
Temperature (hyperthermia vs. normothermia) 1.19 3.27 0.04 1.11–10.64
Comorbidity (affecting health vs. incidental) 2.89 16.7 0.02 2.02–416.67
Idiopathic epilepsy interval (outside vs. inside) 0.86 2.38 0.09 0.88–6.90
TABLE 2 | Multivariate model.
Multivariate model Estimate OR P-value 95% CI (2.5–97.5%)
First seizure outside idiopathic interval 1.28 3.57 0.04 1.11–13.33
Hyperthermia vs. normothermia 1.88 6.67 0. 005 1.84–27.67
No previous AED in epileptic patient 3.02 16.67 0.01 2.90–436.61
we were able to identify several risk factors, directly assessable
upon hospital admission, associated with poor prognosis in dogs
affected by CS or SE.
Age at seizure onset outside the idiopathic interval was found
to predispose epileptic patients to a poor outcome. This may
be explained by the underlying etiology of seizure activity. A
presumptive diagnosis of idiopathic epilepsy has been associated
with the occurrence of the first epileptic seizures between age
6 months and 6 years, along with other diagnostic parameters
such as unremarkable interictal clinical and neurological
examination and unremarkable blood tests (11). When seizure
activity is detected for the first time outside this time interval,
we may assume that the patient is more probably affected by
structural epilepsy, also in the absence of neurological deficits
on interictal neurological examination (16); this etiology has
been reported to be associated with a worse outcome (4, 5, 17).
Patients with reactive seizures were potentially included in the
present study, which may constitute a study bias since reactive
seizures can occur independent of age and not necessarily
associated with other neurological abnormalities besides
seizures (18).
Among the patients with a history of seizures, not receiving
AED treatment was more than 16 times more frequent in those
with a poor outcome. In human medicine, evidence indicates
that early initiation of seizure treatment improves the outcome
of patients affected by SE (19–21), and this concept can be
reasonably extended to veterinary patients as well (22). Patients
who experience recurrent seizures prior to initiation of treatment
are, in fact, more likely to develop pharmacoresistant epilepsy
due to kindling effects (23). The absence of AED treatment in the
patients with a history of seizures might also have been due to the
fact that the first episode occurred shortly before hospitalization.
But this does not seem to be entirely the case because the mean
length of time between first seizure and hospitalization was
similar for the patients with a history of seizures and receiving
AED therapy and those not receiving antiepileptic treatment. In
brief, a plausible reason for not receiving AEDs despite a history
of seizures could be lack of responsiblemanagement by the owner
or a low frequency of seizure episodes.
Polytherapy has been associated with a higher risk of sudden,
unexpected death in epilepsy in human medicine, though it has
also been postulated that this association may be a marker for
severity of epilepsy (24). We found no statistically significant
difference in outcome of epileptic dogs receiving one or more
AEDs; this finding is shared by previous studies (5).
Among the clinical vital signs recorded in an emergency
setting, the only statistically significant variable we identified
was rectal temperature. Increased rectal temperature was more
frequently recorded in patients who died during hospital stay.
Hyperthermia can result from severe muscular contraction
secondary to seizure activity: the longer the duration of seizure
activity, the higher the body temperature rises, and the worse
the clinical condition. Also, prolonged muscle contractions and
hyperthermia can lead to rhabdomyolysis and myoglobinuria,
which may compromise renal function when co-occurring with
hypotension and severe metabolic acidosis (22, 25, 26). Similar
conclusions can be drawn for the association found between
hyperthermia and SE presentation, even if rhabdomyolysis and
clinical consequences were not detected in any of the cases in
the study.
Univariate statistical analysis showed an almost eight-fold
higher likelihood of short-term poor outcome among the patients
who developed in-hospital complications; however, this variable
did not retain significance on multivariate statistical analysis.
The difference can be explained by the low number of patients
that developed in-hospital complications. Since infection, cardiac
dysfunction, and respiratory failure are complications of
prognostic importance in SE outcome in humans (27, 28), it is
reasonable to assume that complications can worsen the outcome
of a severe neurological condition by worsening a patient’s
clinical status.
We evaluated comorbidities because they are a variable of
interest in a scoring system developed in human medicine
for patients with SE (29). Methods for measuring comorbidity
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in human medicine are classified as either a “disease count”
(enumeration of the number of conditions present) or an “index.”
Among the human indexes that have been developed, some rate
the comorbidity burden according to a system that assesses the
effect of the condition on specific body systems, while others list
clearly defined diagnoses. In both methods the conditions are
further described by ranking the severity (30–32). Although the
data in human literature show that indexes are more accurate
than a simple count, such indexes have not been defined for
veterinary patients. As the comorbidities recorded in our study
sample differed from those included in human index lists, a
simple count was made. Analysis showed no association between
comorbidity and outcome when we compared the dogs with
comorbidities (one or more) and those without comorbidities
or when we made a disease count. We also categorized the
comorbidities into those likely to be incidental and those
possibly affecting current health status and/or seizure control.
The latter category was more frequently detected in patients
displaying a poor outcome. As for the development of in-hospital
complications, comorbidities affecting current health can worsen
the outcome of a severe neurological condition by worsening a
patient’s clinical status.
Despite the clear evidence that SE is a more severe condition
than CS (22, 26, 33), we found no significant association between
clinical presentation and outcome. Both conditions can vary in
severity, duration (SE and CS), and frequency (CS). Statistical
analysis was not performed to investigate this aspect, however,
because the information on seizure duration and frequency was
often inconsistent in the clinical chart notes based on the owners’
reports, and the retrospective nature of the study precluded the
possibility to obtain reliable data regarding these variables.
Older age at hospitalization was not found to be associated
with outcome. A bias that might have influenced this result is the
fact that smaller breeds generally live longer than larger breeds,
so age burden may differ among breeds and sizes (34). In the
present study sample, there were no significant differences in the
distribution of small and large breed dogs for the total sample or
between survivors and non-survivors, so it is unlikely that this
confounding factor influenced our results.
A history of prior seizures was evaluated as a potential
prognostic factor: the Status Epilepticus Severity Score is a
prognostic score for human patients with SE. It relies on four
significant outcome predictors, including previous history of
seizures (35, 36). In this scoring system, the absence of previous
seizures is considered a surrogate of acute symptomatic etiology
and a risk factor for death (36). We found no similar association,
however. The majority of the dogs in our study had a history
of generalized seizures; we found no association between type
of seizure activity and outcome. We did not divide generalized
seizures into their various subtypes (tonic-clonic, clonic, tonic,
atonic, or absence) nor did we distinguish focal seizures in
motor, behavioral, and autonomic. Finally, we did not assess the
specific weight of clinical manifestations of seizure activity on
outcome. SE can be further classified as either convulsive or non-
convulsive. Although non-convulsive generalized SE is associated
with a worse outcome according to human scoring systems
(36), such seizure activity can be diagnosed only by means
of electroencephalographic monitoring, a tool not available in
many veterinary services and not routinely performed at our
institution. For these reasons, this variable was not included in
our analysis.
Neither glucose nor lactate blood level was statistically
associated with outcome. The association between elevated
lactate plasma concentration at admission and mortality has
been well-documented in dogs, with non-survivors noted to have
significantly higher lactate concentration compared to survivors.
Furthermore, lactate concentration is a significant predictor
of mortality in the acute patient physiologic and laboratory
evaluation scoring system, a veterinary disease severity scoring
system (37, 38). It has been reported, however, that subsequent
lactate level measurement outperformed the single measurement
at admission, so it is now clear that a greater risk of death is
associated with persistent hyperlactatemia rather than a single
time point finding of elevated lactate concentration (38). These
observations may explain the absence of a significant result in
our study, given that lactate concentrations were evaluated only
at admission and further measurements were not entered into
the analysis.
Hyperglycemia is another predictor variable in the acute
patient physiologic and laboratory evaluation scoring system,
though the authors concluded that stress hyperglycemia was
more probably the manifestation of an epiphenomenon rather
than a truly causative factor for mortality (37). In neurology, and
in head trauma patients in particular, hyperglycemia has been
associated in both human and veterinary medicine with injury
severity but not outcome (39–41). Our study results seem to
confirm these findings.
While we found no statistically significant association between
sex and outcome, there was a slightly higher prevalence of
epileptic seizures among the male dogs (42, 43). Several studies
have reported conflicting data on the predisposition to seizures
of spayed compared to sexually intact females (4, 7); we found
no association that demonstrated a significantly higher risk of
developing seizures in intact compared to neutered females.
The mortality and survival rates of dogs with CS and SE in the
present study are consistent with previous studies that applied
similar inclusion criteria (7). Some reported a higher in-hospital
mortality of 38.5% albeit based on a higher rate of euthanasia
(33% among hospitalized dogs) (4). The percentages of short-
term mortality due to spontaneous death are comparable: 5.4
and 5.1% in our study and in the study by Zimmermann
and colleagues, respectively. Bateman et al. described similar
percentages as well: 2.1% died spontaneously and 23.2% were
euthanized (4, 7).
In our study, hypoglycemia at presentation was associated
with SE presentation. The role of glucose in the pathophysiology
of epileptic seizures, and in SE in particular, is debated. Energy
deprivation via either hypoxia or hypoglycemia often results in
coma and neuronal death and it is sometimes associated with
the onset of seizure activity (44, 45). Nevertheless, the human
literature reports that several systemic changes can occur during
SE, including a decrease in glucose blood concentration (20).
From this point of view, hypoglycemia may not be a cause but
rather a consequence. Furthermore, in vitro recordings have
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shown that low glucose levels might also affect seizure duration,
reducing the frequency and the amplitude in the seizure-like
discharge by 50 and 25%, respectively (46). According to the
ketogenic diet rationale, increasing calorie restriction results in
improved seizure control in epileptic mice; though the exact
mechanisms underlying its clinical efficacy remain unknown
(47). In veterinarymedicine, dogs suffering from reactive seizures
(frequently caused by hypoglycemia) were reported to have a
1.57 higher odds for developing SE than dogs with idiopathic
epilepsy (6).
The main limitation of our study is that both euthanasia
and spontaneous death were defined as poor outcome. The
degree to which the frequency of euthanasia outweighs “natural”
death in veterinary medicine poses a unique challenge to models
developed on mortality outcome, as it is mainly influenced
by owner disposition (48). We attempted to overcome this
limitation by examining the reasons for euthanasia. The owners’
attitude and economic status did not influence the outcome
in any case. They opted for euthanasia due to the persistence
of uncontrolled seizure activity despite treatment or to severe
worsening of the neurological condition. Only one patient was
euthanized because of concurrent severe systemic disease. In
addition, the owner’s personal attitude, financial situation, and
lifestyle may have influenced the greater or lesser effectiveness of
AED therapy and the report of a previous history of seizures.
Inclusion of seizure etiology among the variables would have
certainly enhanced the value of our study, but very often seizure
causes can only be detected after ancillary diagnostic exams,
requiring a delay of up to several hours or days after admission,
which may be critical for therapeutic management. The aim of
this study was to evaluate the clinical and demographic features
that can be assessed at hospital admission.
With this study we wanted to identify risk factors associated
with short-term outcome in dogs with CS or SE. Multivariate
analysis showed that age at first seizure outside the idiopathic
interval, absence of previous AED therapy in dogs with a history
of seizures, and increased rectal temperature were the only
factors that were statistically different between the dogs that
survived and those that did not. Recently developed diagnosis-
independent veterinary scores can be used to benchmark
performance and establish protocols for triage and therapeutic
management. Appropriate reference scores can be used for
objective measurement of illness severity and improve analysis
of treatment outcome significantly (48). With this in mind, the
present study was designed to implement data for the creation
of an ad hoc scoring system, similar to systems currently applied
in human medicine, for use upon hospital admission of patients
with CS or SE.
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